It took almost 20 years for the Nuravax team to develop and characterize its 3rd generation platform and develop multiple vaccines for people at risk of Alzheimer’s disease, tauopathies, Parkinson’s disease and α-synucleopathies using mostly NIA and NINDS R21s, R01s, and U01 awards. Based on positive data, NIA leadership recently supported the development of a SARS-CoV-2 MultiTEP-based vaccine for the elderly.